Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Interest Expenses: 2013-2025

Historic Interest Expenses for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $6.3 million.

  • Amphastar Pharmaceuticals' Interest Expenses fell 6.18% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year decrease of 24.26%. This contributed to the annual value of $30.3 million for FY2024, which is 11.73% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Interest Expenses is $6.3 million, which was up 0.05% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Interest Expenses ranged from a high of $13.7 million in Q3 2023 and a low of $86,000 during Q2 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Interest Expenses averaged around $6.9 million, with its median value being $6.4 million (2024).
  • Its Interest Expenses has fluctuated over the past 5 years, first skyrocketed by 2,320.85% in 2023, then slumped by 51.12% in 2024.
  • Amphastar Pharmaceuticals' Interest Expenses (Quarterly) stood at $168,000 in 2021, then soared by 214.29% to $528,000 in 2022, then skyrocketed by 1,690.91% to $9.5 million in 2023, then crashed by 32.05% to $6.4 million in 2024, then fell by 6.18% to $6.3 million in 2025.
  • Its Interest Expenses stands at $6.3 million for Q3 2025, versus $6.3 million for Q2 2025 and $6.3 million for Q1 2025.